1
|
Banerji B, Chatterjee S, Killi SK, Srinivas D, Prodhan C, Katarkar A, Chaudhuri K. Synthesis and DNA-Binding Studies of A New Cyclic Dimeric Symmetrical Pseudo-Turn Mimetic. ChemistrySelect 2018. [DOI: 10.1002/slct.201703062] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Affiliation(s)
- Biswadip Banerji
- Organic & Medicinal Chemistry Division; Indian Institute of Chemical Biology (CSIR-IICB); 4 Raja S. C. Mullick Road Kolkata India-700032
- Academy of Scientific and Innovative Research (AcSIR); 4 Raja S. C. Mullick Road Kolkata India-700032
| | - Satadru Chatterjee
- Organic & Medicinal Chemistry Division; Indian Institute of Chemical Biology (CSIR-IICB); 4 Raja S. C. Mullick Road Kolkata India-700032
| | - Sunil Kumar Killi
- Organic & Medicinal Chemistry Division; Indian Institute of Chemical Biology (CSIR-IICB); 4 Raja S. C. Mullick Road Kolkata India-700032
| | - D. Srinivas
- National Institute of Pharmaceutical Research; NIPER-Kolkata; 4 Raja S. C. Mullick Road Kolkata India-700032
| | - Chandraday Prodhan
- Molecular Genetics; Indian Institute of Chemical Biology (CSIR-IICB); 4 Raja S. C. Mullick Road Kolkata India-700032
| | - Atul Katarkar
- Molecular Genetics; Indian Institute of Chemical Biology (CSIR-IICB); 4 Raja S. C. Mullick Road Kolkata India-700032
| | - Keya Chaudhuri
- Molecular Genetics; Indian Institute of Chemical Biology (CSIR-IICB); 4 Raja S. C. Mullick Road Kolkata India-700032
| |
Collapse
|
2
|
|
3
|
DNA binders in clinical trials and chemotherapy. Bioorg Med Chem 2014; 22:4506-21. [DOI: 10.1016/j.bmc.2014.05.030] [Citation(s) in RCA: 79] [Impact Index Per Article: 7.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/23/2014] [Revised: 05/09/2014] [Accepted: 05/14/2014] [Indexed: 01/09/2023]
|
4
|
Srivastava HK, Chourasia M, Kumar D, Sastry GN. Comparison of Computational Methods to Model DNA Minor Groove Binders. J Chem Inf Model 2011; 51:558-71. [DOI: 10.1021/ci100474n] [Citation(s) in RCA: 54] [Impact Index Per Article: 4.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/02/2023]
Affiliation(s)
- Hemant Kumar Srivastava
- Molecular Modelling Group, Indian Institute of Chemical Technology, Taranaka, Hyderabad 500 607, India
| | - Mukesh Chourasia
- Molecular Modelling Group, Indian Institute of Chemical Technology, Taranaka, Hyderabad 500 607, India
| | - Devesh Kumar
- Molecular Modelling Group, Indian Institute of Chemical Technology, Taranaka, Hyderabad 500 607, India
| | - G. Narahari Sastry
- Molecular Modelling Group, Indian Institute of Chemical Technology, Taranaka, Hyderabad 500 607, India
| |
Collapse
|
5
|
Lorusso D, Mainenti S, Pietragalla A, Ferrandina G, Foco G, Masciullo V, Scambia G. Brostallicin (PNU-166196), a new minor groove DNA binder: preclinical and clinical activity. Expert Opin Investig Drugs 2009; 18:1939-46. [DOI: 10.1517/13543780903401284] [Citation(s) in RCA: 25] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
|
6
|
Cai X, Gray PJ, Von Hoff DD. DNA minor groove binders: back in the groove. Cancer Treat Rev 2009; 35:437-50. [PMID: 19328629 DOI: 10.1016/j.ctrv.2009.02.004] [Citation(s) in RCA: 74] [Impact Index Per Article: 4.9] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/12/2009] [Accepted: 02/16/2009] [Indexed: 01/17/2023]
Abstract
With recent approval of the minor groove binding agent trabectidin in Europe for the treatment of patients with soft tissue sarcomas, there has been renewed interest in minor groove binders. Though previously considered to be without clinical value due to their initial significant toxicities, new minor groove binders are emerging which are challenging that perception. Toxicities in the most recently completed and ongoing trials have been easily manageable. These agents have demonstrable anti-tumor activity against a wide variety of tumor types including leukemias, sarcomas, melanomas, breast and ovarian cancers. Applying these agents according to a particular tumor's context of vulnerability might reveal previously unconsidered applications for this diverse class of agents. This review provides a look at how minor groove binding agents have progressed from the lab through the clinic with particular emphasis on identifying the contexts of vulnerabilities of patient tumors which increase the effectiveness of these drugs.
Collapse
Affiliation(s)
- Xuemei Cai
- Harvard Medical School, Boston, MA 02215, United States.
| | | | | |
Collapse
|
7
|
Beria I, Baraldi PG, Cozzi P, Caldarelli M, Geroni C, Marchini S, Mongelli N, Romagnoli R. Cytotoxic α-Halogenoacrylic Derivatives of Distamycin A and Congeners. J Med Chem 2004; 47:2611-23. [PMID: 15115402 DOI: 10.1021/jm031051k] [Citation(s) in RCA: 35] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/23/2023]
Abstract
The mechanism of action of many antitumor agents involves DNA damage, either by direct binding of the drug to DNA or to DNA-binding proteins. However, most of the DNA-interacting agents have only a limited degree of sequence specificity, which implies that they may hit all the cellular genes. DNA minor groove binders, among which the derivatives of distamycin A play an important role, could provide significant improvement in cancer management, increasing gene specificity, due to high selectivity of interaction with thymine-adenine (TA) rich sequences. We now report and discuss the synthesis, the in vitro and in vivo activities, and some mechanistic features of alpha-halogenoacrylamido derivatives of distamycin A. The final result of this work was the selection of brostallicin 17 (PNU-166196). Brostallicin, presently in phase II clinical trials, shows a broad spectrum of antitumor activity and an apoptotic effect higher than distamycin derivative tallimustine. An important in vitro toxicological feature of brostallicin is the very good ratio between myelotoxicity on human haematopoietic progenitor cells and cytotoxicity on tumor cells, in comparison with clinically tested DNA minor groove binders. A peculiarity of brostallicin is its in vitro reactivity in the DNA alkylation assays only in the presence of glutathione. Moreover brostallicin's antitumor activity, both in in vitro and in vivo tumor models, is higher in the presence of increased levels of glutathione/glutathione-S-tranferases. These findings contribute to the definition of brostallicin as a novel anticancer agent that differs from other minor groove binders and alkylating agents for both the profile of activity and the mechanism of action and to classify the alpha-bromoacrylamido derivatives of distamycin as a new class of cytotoxics. Moreover, due to its interaction with glutathione, brostallicin may have a role for the tailored treatment of tumors characterized by constitutive or therapy-induced overexpression of glutathione/glutathione-S-tranferase levels.
Collapse
Affiliation(s)
- Italo Beria
- Pharmacia Italia S.p.A., Discovery Research Oncology, Viale Pasteur 10, 20014 Nerviano, Milan, Italy.
| | | | | | | | | | | | | | | |
Collapse
|
8
|
Broggini M, Marchini S, Fontana E, Moneta D, Fowst C, Geroni C. Brostallicin: a new concept in minor groove DNA binder development. Anticancer Drugs 2004; 15:1-6. [PMID: 15090736 DOI: 10.1097/00001813-200401000-00001] [Citation(s) in RCA: 27] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Brostallicin is a bromoacryloyl derivative of distamycin A, which has shown very promising preclinical activity against a variety of human tumors both in vitro and in vivo. The drug has a limited toxicity towards bone marrow precursor cells in vitro resulting in a therapeutic index much higher than those achieved with other distamycin A derivatives. It retains activity against cancer cells resistant to alkylating agents, topoisomerase I inhibitors and cells with mismatch repair deficiency. Brostallicin has a peculiar mechanism of action involving activation upon binding to glutathione (GSH) catalyzed by glutathione-S-transferase (GST). As a consequence, cells expressing relatively high GST/GSH levels are more susceptible to treatment with brostallicin. Considering that increased levels of GST/GSH are often found in human tumors, this could represent an advantage for the drug in the clinic. Initial clinical studies indicate the tolerability of the drug and allow the determination of the optimal dose for subsequent studies. Some partial response were obtained in these initial phase I studies. Altogether, the results suggest brostallicin to be a new promising anticancer agent with a new mechanism of action. It also raises the possibility to use it in combination with other anticancer drugs currently used.
Collapse
Affiliation(s)
- Massimo Broggini
- Laboratory of Molecular Pharmacology, Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy.
| | | | | | | | | | | |
Collapse
|
9
|
Fedier A, Fowst C, Tursi J, Geroni C, Haller U, Marchini S, Fink D. Brostallicin (PNU-166196)--a new DNA minor groove binder that retains sensitivity in DNA mismatch repair-deficient tumour cells. Br J Cancer 2003; 89:1559-65. [PMID: 14562032 PMCID: PMC2394335 DOI: 10.1038/sj.bjc.6601316] [Citation(s) in RCA: 29] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
Defects in DNA mismatch repair (MMR) are associated with a predisposition to tumorigenesis and with drug resistance owing to high mutation rates and failure to engage DNA-damage-induced apoptosis. DNA minor groove binders (MGBs) are a class of anticancer agents highly effective in a variety of human cancers. Owing to their mode of action, DNA MGB-induced DNA damage may be a substrate for DNA MMR. This study was aimed at investigating the effect of loss of MMR on the sensitivity to brostallicin (PNU-166196), a novel synthetic α-bromoacrylic, second-generation DNA MGB currently in Phase II clinical trials and structurally related to distamycin A. Brostallicin activity was compared to a benzoyl mustard derivative of distamycin A (tallimustine). We report that the sensitivities of MLH1-deficient and -proficient HCT116 human colon carcinoma cells were comparable after treatment with brostallicin, while tallimustine resulted in a three times lower cytotoxicity in MLH1-deficient than in -proficient cells. MSH2-deficient HEC59 parental endometrial adenocarcinoma cells were as sensitive as the proficient HEC59+ch2 cells after brostallicin treatment, but were 1.8-fold resistant after tallimustine treatment as compared to the MSH2-proficient HEC59+ch2 counterpart. In addition, p53-deficient mouse fibroblasts lacking PMS2 were as sensitive to brostallicin as PMS2-proficient cells, but were 1.6-fold resistant to tallimustine. Loss of neither ATM nor DNA-PK affected sensitivity to brostallicin in p53-deficient mouse embryonic fibroblasts, indicating that brostallicin-induced cytotoxicity in a p53-deficient genetic background does not seem to require these kinases. These data show that, unlike other DNA MGBs, MMR-deficient cells retain their sensitivity to this new α-bromoacrylic derivative, indicating that brostallicin-induced cytotoxicity does not depend on functional DNA MMR. Since DNA MMR deficiency is common in numerous types of tumours, brostallicin potentially offers the advantage of being effective against MMR-defective tumours that are refractory to several anticancer agents.
Collapse
Affiliation(s)
- A Fedier
- Department of Obstetrics and Gynaecology, Division of Gynaecology, University Hospital of Zurich, CH-8091, Switzerland
| | - C Fowst
- Pharmacia Italy, Oncology, Nerviano, Italy
| | - J Tursi
- Pharmacia Italy, Oncology, Nerviano, Italy
| | - C Geroni
- Pharmacia Italy, Oncology, Nerviano, Italy
| | - U Haller
- Department of Obstetrics and Gynaecology, Division of Gynaecology, University Hospital of Zurich, CH-8091, Switzerland
| | - S Marchini
- Istituto di Ricerche Farmacologiche Mario Negri, Milano, Italy
| | - D Fink
- Department of Obstetrics and Gynaecology, Division of Gynaecology, University Hospital of Zurich, CH-8091, Switzerland
- Department of Obstetrics and Gynaecology, Division of Gynaecology, University Hospital of Zurich, CH-8091, Switzerland. E-mail:
| |
Collapse
|
10
|
Baraldi PG, Beria I, Cozzi P, Bianchi N, Gambari R, Romagnoli R. Synthesis and growth inhibition activity of alpha-bromoacrylic heterocyclic and benzoheterocyclic derivatives of distamycin A modified on the amidino moiety. Bioorg Med Chem 2003; 11:965-75. [PMID: 12614881 DOI: 10.1016/s0968-0896(02)00533-3] [Citation(s) in RCA: 18] [Impact Index Per Article: 0.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
The design, synthesis and in vitro activities of novel alpha-bromoacryloyl pyrazole, imidazole and benzoheterocyclic derivatives of distamycin A, in which the amidino moiety has been replaced by moieties of different physico-chemical features are described, and the structure-activity relationships are discussed. In spite of the relevance of these modifications on the distamycin frame, these derivatives showed significant growth inhibitory activity against mouse leukemia L1210 cells. Therefore, the presence of the amidino moiety, and in general of a basic moiety, is not an absolute requirement for biological activity of alpha-bromoacrylic derivatives of distamycin.
Collapse
|
11
|
Mann J, Baron A, Opoku-Boahen Y, Johansson E, Parkinson G, Kelland LR, Neidle S. A new class of symmetric bisbenzimidazole-based DNA minor groove-binding agents showing antitumor activity. J Med Chem 2001; 44:138-44. [PMID: 11170623 DOI: 10.1021/jm000297b] [Citation(s) in RCA: 204] [Impact Index Per Article: 8.9] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/17/2022]
Abstract
The synthesis and evaluation of the novel head-to-head bisbenzimidazole compound 2,2-bis[4'-(3' '-dimethylamino-1' '-propyloxy)phenyl]-5,5-bi-1H-benzimidazole is described. An X-ray crystallographic study of a complex with the DNA dodecanucleotide sequence d(CGCGAATTCGCG) shows the compound bound in the A/T minor groove region of a B-DNA duplex and that the head-to-head bisbenzimidazole motif hydrogen-bonds to the edges of all four consecutive A:T base pairs. The compound showed potent growth inhibition with a mean IC(50) across an ovarian carcinoma cell line panel of 0.31 microM, with no significant cross-resistance in two acquired cisplatin-resistant cell lines and a low level of cross-resistance in the P-glycoprotein overexpressing acquired doxorubicin-resistant cell line. Studies with the hollow fiber assay and in vivo tumor xenografts showed some evidence of antitumor activity.
Collapse
Affiliation(s)
- J Mann
- Chemistry Department, Reading University, Whiteknights, Reading RG6 6AD, UK
| | | | | | | | | | | | | |
Collapse
|
12
|
Simpson IJ, Lee M, Kumar A, Boykin DW, Neidle S. DNA minor groove interactions and the biological activity of 2,5-bis. Bioorg Med Chem Lett 2000; 10:2593-7. [PMID: 11128631 DOI: 10.1016/s0960-894x(00)00511-4] [Citation(s) in RCA: 30] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]
Abstract
2,5-Bis-[4-(N-cyclobutyl-amidino)phenyl] furan and 2,5-bis-[4-(N-cyclohexyl-amidino)phenyl] furan have activity against Pneumocystis carinii and also show cytotoxicity against several tumour cell lines. These activities are correlated with DNA-binding abilities; the crystal structures of complexes with the DNA sequence d(CGCGAATTCGCG) is reported here. Interactions with, and effects on, the DNA minor groove, are found to be factors in the biological properties of these compounds.
Collapse
Affiliation(s)
- I J Simpson
- CRC Biomolecular Structure Unit, Chester Beatty Laboratories, The Institute of Cancer Research, London, UK
| | | | | | | | | |
Collapse
|
13
|
Cozzi P, Beria I, Caldarelli M, Capolongo L, Geroni C, Mongelli N. Cytotoxic halogenoacrylic derivatives of distamycin A. Bioorg Med Chem Lett 2000; 10:1269-72. [PMID: 10866397 DOI: 10.1016/s0960-894x(00)00204-3] [Citation(s) in RCA: 26] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/17/2022]
Abstract
The design, synthesis, in vitro and in vivo activities of a series of halogenoacrylic derivatives of distamycin A are described. The structure-activity relationships indicate a key role of the reactivity of alpha-halogenoacrylic moiety. The reactivity and the putative alkylating mechanism of these compounds are different from those of the nitrogen mustards and possibly based on a Michael type reaction. This supports the hypothesis that these compounds represent a class of minor groove binders mechanistically different from tallimustine.
Collapse
Affiliation(s)
- P Cozzi
- Department of Chemistry, Pharmacia & Upjohn, Discovery Research Oncology, Milan, Italy.
| | | | | | | | | | | |
Collapse
|
14
|
Cozzi P, Beria I, Caldarelli M, Geroni C, Mongelli N, Pennella G. Cytotoxic alpha-bromoacrylic derivatives of distamycin analogues modified at the amidino moiety. Bioorg Med Chem Lett 2000; 10:1273-6. [PMID: 10866398 DOI: 10.1016/s0960-894x(00)00205-5] [Citation(s) in RCA: 23] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
Abstract
The design, synthesis, in vitro and in vivo activities of novel alpha-bromoacrylic derivatives of distamycin A, modified at the amidino moiety by the replacement with basic or non-basic groups are reported. In spite of the relevance of these modifications of distamycin frame, the new derivatives are potent cytotoxics. The presence of the amidino moiety, is, therefore; not an absolute requirement for the activity. In particular due to a favorable myelotoxicity/cytotoxicity ratio, guanidino derivative PNU 166196 was selected for clinical development.
Collapse
Affiliation(s)
- P Cozzi
- Department of Chemistry, Pharmacia & Upjohn, Discovery Research Oncology, Milan, Italy.
| | | | | | | | | | | |
Collapse
|
15
|
Cozzi P. Recent outcome in the field of distamycin-derived minor groove binders. FARMACO (SOCIETA CHIMICA ITALIANA : 1989) 2000; 55:168-73. [PMID: 10919073 DOI: 10.1016/s0014-827x(00)00013-6] [Citation(s) in RCA: 16] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
DNA minor groove binders represent a class of cytotoxic antitumor agents whose DNA sequence specificity may lead to a high selectivity of action. Tallimustine, benzoyl nitrogen mustard derivative of distamycin A, showed excellent antitumor activity in the preclinical tests, but as other minor groove binders, showed severe myelotoxicity. Novel nitrogen mustard derivatives of distamycin showing improved activity profile, have been identified recently. Moreover, a series of alpha-halogenoacrylamido derivatives of distamycin-like frames, in which the typical amidino moiety has been replaced with other moieties, was found to show cytotoxic and antitumor activity and cytotoxicity/myelotoxicity ratio improved significantly in comparison to tallimustine. The structural features of the alkylating moieties and binding frames, of distamycin and distamycin-like derivatives disclosed recently are discussed.
Collapse
Affiliation(s)
- P Cozzi
- Department of Chemistry, Pharmacia & Upjohn, Nerviano, Milan, Italy.
| |
Collapse
|